• In late June 2026, Gilead Sciences reported that the FDA and European Commission approved Trodelvy for first-line treatment of unresectable locally advanced or metastatic triple-negative breast cancer, backed by Phase 3 ASCENT-03 and ASCENT-04 data showing clinically meaningful progression-free survival advantages over chemotherapy-based regimens.
• These decisions elevate Trodelvy’s role in HER2-negative breast cancer care, potentially expanding its use across PD-L1 statuses and reinforcing Gilead’s position in antibody-drug conjugates targeting Trop-2–expressing tumors.
• We’ll now examine how Trodelvy’s first-line approvals in the U.S. and Europe may reshape Gilead’s HIV-and-oncology-led investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Gilead Sciences Investment Narrative Recap

To own Gilead, you need to believe its HIV cash flows and growing oncology franchise can offset policy pressure and eventual HIV patent expiries. The near term catalyst is Trodelvy’s expansion in breast cancer, and first line approvals in the US and Europe look supportive rather than transformative against that backdrop. The biggest current risk remains execution in broadening access and reimbursement for newer drugs across markets, rather than this specific label update.

Among recent announcements, the series of Trodelvy approvals in late June 2026 is most relevant. The FDA green light for first line metastatic triple negative breast cancer, backed by ASCENT 03 and ASCENT 04 data and mirrored in the European authorization, directly links to Gilead’s effort to diversify beyond HIV. How well Trodelvy converts strong clinical data into sustained uptake will be central to whether oncology meaningfully reshapes the company’s earnings mix.

Yet beneath the Trodelvy momentum, investors should also be aware of growing pricing and reimbursement pressure that could...

Gilead Sciences’ narrative projects $34.5 billion revenue and $10.8 billion earnings by 2029.

Uncover how Gilead Sciences' forecasts yield a $157.83 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already expecting revenue near US$38.1 billion and earnings around US$12.7 billion by 2029, so if you see Trodelvy’s new approvals as easing the heavy dependence on future launches that worried them, you may view this news as strengthening a more aggressive growth case than the baseline narrative suggests.

Explore 6 other fair value estimates on Gilead Sciences - why the stock might be worth just $128.38!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Gilead Sciences research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Gilead Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Gilead Sciences' overall financial health at a glance.

Curious About Other Options?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.